Zobrazeno 1 - 6 of 6 pro vyhledávání: '"D. B. Duggan"'
1
Phase III Study of Cyclophosphamide, Doxorubicin, and Fluorouracil (CAF) Plus Leucovorin Versus CAF for Metastatic Breast Cancer: Cancer and Leukemia Group B 9140
Autor: Joseph Aisner, Howard L. Parnes, S. L. Allen, Donald A. Berry, D. B. Duggan, Michael C. Perry, T. P. Szatrowski, Larry Norton, J. Abrams, I. C. Henderson, M. R. Cooper, Constance Cirrincione, E. Chuang
Publikováno v: Journal of Clinical Oncology. 21:1819-1824
Purpose: To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer. Patients and Methods: Women with histologically confirmed stage
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8004f9d65731b38e78f2396bccd034d
https://doi.org/10.1200/jco.2003.05.119
Zobrazit plný text záznamu
2
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662
Autor: D F, Hayes, H, Yamauchi, G, Broadwater, C T, Cirrincione, S P, Rodrigue, D A, Berry, J, Younger, L L, Panasci, F, Millard, D B, Duggan, L, Norton, I C, Henderson
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 7(9)
The HER-2/erbB-2/c-neu (HER-2) proto-oncogene is a M(r) 185,000 transmembrane tyrosine kinase that is amplified and/or overexpressed by 20-40% of breast cancers. HER-2 has been associated with worse prognosis and resistance or sensitivity to specific
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ddbe2c7cdd2a06c54ae5218b28b9baa9
https://pubmed.ncbi.nlm.nih.gov/11555569
Zobrazit plný text záznamu
3
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study
Autor: S L, Graziano, J E, Herndon, F, Richards, S, DiFino, C, Modeas, D B, Duggan, M R, Green
Publikováno v: Cancer. 72(1)
This Phase I study was designed to determine the maximum tolerated dose of ifosfamide-mesna with a fixed dose of cisplatin without growth factor or hematopoietic precursor support.Twenty-five patients with previously untreated advanced non-small cell
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2933c39cfa8f6401999b120ae2652657
https://pubmed.ncbi.nlm.nih.gov/8389667
Zobrazit plný text záznamu
4
A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy
Autor: W L, Ramseur, F, Richards, D B, Duggan
Publikováno v: Cancer. 63(10)
Beta interferon (beta-IFN) and interleukin-2 (IL-2) have been utilized in experimental cancer therapy because of their effects on the immune system. We report here a patient treated with IL-2 and beta-IFN who rapidly developed an immune-mediated, bul
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e960b967255c19553ae9146974982026
https://pubmed.ncbi.nlm.nih.gov/2649223
Zobrazit plný text záznamu
5
Unusual manifestations of monoclonal gammopathies. Autoimmune and idiopathic syndromes
Autor: D B, Duggan, A, Schattner
Publikováno v: The American journal of medicine. 81(5)
Manifestations of monoclonal gammopathies are due to four broad mechanisms: destruction of bones, bone marrow, and normal tissues by an expanding tumor; nonspecific effects of large amounts of circulating paraproteins leading to hyperviscosity; autoa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9a48beb0aa4fd55a0267085e2b4adfcc
https://pubmed.ncbi.nlm.nih.gov/3535495
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje